Epineuron Receives First Patent Issuance for Peripheral Nerve Regeneration Technology

Date: March 17, 2020

Epineuron, a leading innovator of bioelectronic solutions for nerve repair and regeneration, is thrilled to announce the issuance of its first patent by the United States Patent and Trademark Office for its ground-breaking peripheral nerve regeneration technology. This milestone achievement underscores the company's commitment to revolutionizing the field of nerve repair and enhancing the lives of patients worldwide.

The newly issued patent, US 10,589,089, recognizes Epineuron's pioneering research and breakthrough discoveries in the area of peripheral nerve regeneration. The cutting-edge technology has the potential to transform the way nerve injuries are treated, offering hope to countless individuals suffering from debilitating conditions and injuries.

Peripheral nerve damage affects millions of people globally, causing loss of sensation, mobility, and functionality. Until now, treatment options have been limited, often resulting in suboptimal outcomes and prolonged recovery periods. With this patent, Epineuron is poised to revolutionize the field by introducing innovative solutions that address these challenges head-on.

"We are immensely proud of this patent issuance, which represents a significant milestone in our journey towards advancing the frontiers of nerve repair," said Sergio Aguirre, CEO at Epineuron. "Building on the pioneering scientific work of our esteemed advisors and combined with our relentless dedication to technological innovation, Epineuron has paved the way for ground-breaking discoveries in peripheral nerve regeneration.”

The patented technology developed by Epineuron combines state-of-the-art surgical techniques with a novel bioelectronic therapeutic to enhance the regrowth of damaged nerves, facilitating the restoration of impacted physiological functions. This breakthrough holds promise for a wide range of applications, including the treatment of peripheral neuropathies, nerve injuries resulting from trauma, and compression injuries, like carpal and cubital tunnel.

The issuance of this patent solidifies Epineuron's position as a trailblazer in the field of peripheral nerve regeneration. It underscores the company's commitment to innovation, research excellence, and the advancement of healthcare technologies that improve patient outcomes and quality of life. Combined with the FDA Breakthrough Device designation received earlier, this technology is well on its way to commercialization.

As Epineuron continues to pioneer new solutions in nerve repair, it remains dedicated to collaborating with healthcare professionals and research institutions to further advance the field and bring transformative therapies to patients worldwide.